| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total non-operating income (expenses), net | -3,807 | -2,849 | -6,431 | -9,365 |
| Income before income taxes | 21,513 | 39,335 | 30,862 | 47,683 |
| Income tax provision | 4,163 | 8,305 | 5,577 | 7,254 |
| Income before equity in losses of unconsolidated affiliate | 17,350 | 31,030 | 25,285 | 40,429 |
| Net income attributable to amphastar pharmaceuticals, inc | - | - | 25,285 | - |
| Net income | 17,350 | 31,030 | 25,285 | - |
| Earnings per share, basic | 0.38 | 0.66 | 0.53 | 0.83 |
| Earnings per share, diluted | 0.37 | 0.64 | 0.51 | 0.78 |
| Weighted average number of shares outstanding, basic | 46,474,000 | 46,949,000 | 47,641,000 | 48,621,000 |
| Weighted average number of shares outstanding, diluted | 47,677,000 | 48,128,000 | 49,890,000 | 51,862,000 |
Amphastar Pharmaceuticals, Inc. (AMPH)
Amphastar Pharmaceuticals, Inc. (AMPH)